Get the Stockscreener App
29.52
0.54%
0.16
After Hours:
29.71
0.19
+0.64%
Ultragenyx Pharmaceutical Inc stock is traded at $29.52, with a volume of 1.17M.
It is up +0.54% in the last 24 hours and up +11.86% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$29.36
Open:
$29.07
24h Volume:
1.17M
Relative Volume:
0.65
Market Cap:
$2.84B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-4.5626
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+1.76%
1M Performance:
+11.86%
6M Performance:
-30.69%
1Y Performance:
-48.26%
1-Day Range:
$28.85
$29.62
1-Week Range:
$28.85
$30.10
52-Week Range:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
29.52 | 2.86B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Will Ultragenyx Pharmaceutical Inc. Recover After Recent Decline2025 Fundamental Recap & Daily Profit Maximizing Trade Tips - newsyoung.net
Ultragenyx starts FDA marketing application process for its gene therapy - MSN
Machine Learning Models Forecast Ultragenyx Pharmaceutical Inc. UptickBear Alert & Reliable Breakout Forecasts - kangso.co.kr
Ultragenyx Initiates Rolling Submission of Biologics License Application to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia - MarketScreener
Ultragenyx Initiates Rolling BLA Submission for DTX401 Gene Therapy - AInvest
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa Treatment. - AInvest
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401 - TipRanks
Chartists See Breakout Potential in Ultragenyx Pharmaceutical Inc.July 2025 Weekly Recap & AI Enhanced Trade Execution Alerts - 선데이타임즈
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewswire
Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy - TradingView
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt - 富途牛牛
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Ultragenyx Begins FDA Marketing Application for DTX401 Gene Therapy for GSD Type Ia - AInvest
Ultragenyx Begins FDA Application for DTX401 Gene Therapy - TipRanks
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis, Ultragenyx Pharma, GW Pharma, Q-State - Barchart.com
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy - MarketScreener
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa. - AInvest
Ultragenyx Initiates Rolling Submission of Biologics - GlobeNewswire
Ultragenyx Initiates Rolling Submission of Biologics License Application for DTX401 AAV Gene Therapy to Treat GSDIa - AInvest
64% Treatment Success: Ultragenyx's Gene Therapy DTX401 Advances FDA Review for Rare Disease GSDIa - Stock Titan
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
Pomerantz LLP investigates Ultragenyx Pharmaceutical securities fraud claims. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
Will earnings trigger a reversal in Ultragenyx Pharmaceutical Inc.Trade Risk Report & Free High Return Stock Watch Alerts - Newser
Why Ultragenyx (RARE) Is Up 7.8% After Reporting Narrowed Losses and Higher Q2 Revenue - simplywall.st
Will Ultragenyx Pharmaceutical Inc. bounce back from current supportJuly 2025 Market Mood & Accurate Intraday Trade Tips - Newser
How high can Ultragenyx Pharmaceutical Inc. stock goEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Price Clustering Detected in Ultragenyx Pharmaceutical Inc. StockWeekly Trade Summary & Safe Investment Capital Preservation Plans - sundaytimes.kr
Ultragenyx Pharmaceutical Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Community Verified Watchlist Alerts - metal.it
Navigating Legal Storms in Biotech: The Ultragenyx Case and Investor Caution - AInvest
Ultragenyx Pharmaceutical faces securities fraud investigation. - AInvest
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
How sentiment analysis helps forecast Ultragenyx Pharmaceutical Inc.2025 Risk Factors & Safe Capital Allocation Plans - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.July 2025 Trends & Fast Gaining Stock Strategy Reports - Newser
Is Ultragenyx Pharmaceutical Inc. the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - 선데이타임즈
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
RSI Reset May Fuel Rebound in Ultragenyx Pharmaceutical Inc.Wall Street Watch & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - MSN
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):